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A B S T R A C T
Melasma is a common, acquired facial skin disorder, mostly involving sun-exposed areas like cheeks, forehead and
upper lip. Melasma occurs in both sexes, although almost 90 percent of the affected are women. It is more common in
darker skin types (Fitzpatrick skin types IV to VI) especially Hispanics/Latinos, Asians and African-Americans. The on-
set of the melasma is at puberty or later, with exception of darker skin types, who tend to develop this problem in the first
decade of life. The etiology is still unknown, although there are a number of triggering factors related to the onset of
melasma. The most important are sun-exposure and genetic factors in both sexes, while hormonal activity has more im-
portant role in females. In addition, stress and some cosmetic products and drugs containing phototoxic agents can
cause outbreaks of this condition. Melasma should be treated using monotherapies or combination of therapy, mainly
fixed triple or dual combinations containing hydroquinone, tretinoin, corticosteroids or azelaic acid. Modified Klig-
man’s formula is also very effective. Above mentioned therapy regimens in combination with UVA and UVB blocking
sunscreens are mostly effective in epidermal melasma. Discontinuation of the use of birth control pills, scented cosmetic
products, and phototoxic drugs coupled with UV protection are also benefitial in clearing of melasma. Alternative treat-
ment including chemical peels and glicolic acid, seem to have the best result as a second line treatment after bleaching
creams. Laser treatments show limited efficacy and should rarely be used in the treatment of melasma. Combining topical
agents like hydroquinone, tretinoin and a corticosteroid in addition to sun avoidance, regular use of sunscreen through-
out the year and patient education is the best treatment in this difficult to treat condition.
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Introduction
Melasma is common acquired facial skin discolor-
ation, mostly involving cheeks, forehead and upper lip.
Generally, melasma can occur in both sexes, but almost
90 percent of the affected are women. Though any race
and skin type can be affected, darker skin types (Fitz-
patrick skin types IV to VI) especially Hispanics/Latinos,
Asians and African-Americans, have higher incidences of
melasma. The onset of the melasma is mostly noted at
puberty or later, with the exception of darkly races from
India, Pakistan and the Middle East who tend to develop
this problem in the first decade of life1.
The major determinant of normal skin color is the ac-
tivity of melanocytes, quantity and quality of pigment
production and not the density of melanocytes2. Mela-
nocytes contain a unique intracytoplasmic organelle, the
melanosome, which is the site of melanin biosynthesis.
Compared with lightly pigmented skin, dark skin has
melanosomes that contain more melanin and are larger
in diameter. Melanosomes contain tyrosinase, a copper-
-containing enzyme, which catalyzes the conversion of
L-tyrosine to L-dopa and L-dopa to L-dopa-quinone in
melanin synthesis3.
The definite etiology of melasma is uncertain but
there are number of the triggering factors that are re-
lated with the onset of the condition. Exposure to sun-
light and genetic factors4 are significant causative agents
in both sexes, with the addition of hormonal influence in
female. In addition, stress5 and some cosmetic products
and drugs containing phototoxic agents can cause out-
breaks of this condition. Uncontrolled sunlight exposure
is considered the leading cause of melasma, especially in
individuals with a genetic predisposition to this condi-
tion. Some studies have shown that melasma typically
outbursts in the summer months and fading during peri-
ods of sun avoidance6. Melasma is often associated with
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the female hormones estrogen and progesterone. It is es-
pecially common in pregnant women7 (chloasma), wo-
men who are taking birth control pills8 (oral contracep-
tives) and women taking hormone replacement therapy9
(HRT) during menopause. Chloasma (»mask of preg-
nancy«) commonly decreases or disappears after parturi-
tion, especially in lightly pigmented women.
Melasma presents as brown, gray or blue macules
that coalesce into patches with irregular outline emerg-
ing mostly on sun exposed skin. The three major pat-
terns based on clinical findings are the centrofacial pat-
tern (the most common pattern that occurs in two thirds
of melasma patients and affects forehead, nose, chin and
medial cheeks), the malar pattern (appears in about 20%,
only cheeks and nose involved) and the mandibular pat-
tern (appears in 15% of patients, strikes the skin overly-
ing the mandibula)2.
Based on Wood’s lamp examination there are three
major histological types: epidermal (good response to
topical therapy), dermal and mixed. According to some
authors there is a fourth type – Wood’s lamp inaparent –
seen in patients with darker skin type10.
Treatment
Besides skin changes which can mutilate persons ap-
pearance, melasma can cause emotional disturbance.
Treatment of melasma is demanding and, sometimes,
frustrating process due to frequent relapses and varying
success. Reduction of the symptom expression, affected
area, relapses and cosmetic disfigurement in combina-
tion with minimal adverse events are considered to be
the goals of treatment11. Discontinuation of the use of
birth control pills, scented cosmetic products, and photo-
toxic drugs coupled with UV protection12 are obligatory
measurements in combination with topical treatement2.
Topical treatments include hydroquinone cream which is
the most prescribed agent for melasma in monotherapy
or can be used in combination with tretinoin, azelaic acid
or steroids and is considered the gold standard especially
for epidermal melasma. Hydroquinone, tretinoin and
azelaic acid are tyrosinase inhibitors and act directly on
melanogenesis, in contrast to physical therapy like chem-
ical peels, and lasers that remove melanin, rather than
inhibiting melanocytes. If melasma outbursts during preg-
nancy, treatment is postponed since it usually withdraws




Hydroquinone (1,4-dihydroxybenzene) competes with
tyrosine, preventing the enzymatic oxydation of tyrosine
to dopa – melanin precursor2. HQ also inhibits the for-
mation and increases degradation of melanosomes14 and
inhibits the DNA and RNA synthesis of melanocytes15.
HQ is one of the most commonly used depigmentating
agents. It is available at concentrations ranging from 1.5
to 5%. Effectiveness of the HQ is related directly to the
concentration of the preparation, to the vehicle used and
to the chemical stability of the final product16. Higher
concentrations (over 2%) are disposable only by prescrip-
tion. HQ should be applied uniformly twice daily on the
affected area for at least three months and up to one
year17. Most common adverse reactions are skin irrita-
tions (presented as skin itching, burning, stinging) and
allergic dermatitis and are closely related to the applied
dose as well as the duration of the treatment. Chronic
use of high concentration (>5%) can cause ochronosis
and colloid milium5.
Tretinoin
Tretinoin affects the melanisation pathway by in-
creasing epidermal turnover that decreases the contact
time between keratinocytes and melanocytes18 and dis-
rupts melanogenesis by inhibition of tyrosinase activity2.
Tretinoin preparations are available in concentration
ranging from 0.05 to 0.1%. Tretinoin should be combined
with HQ and corticosteroids5. It is mandatory to use UVA
and UVB sun-screens while using tretinoin. The most
frequent adverse events are erythema, burning, stinging,
dryness, and scaling19. There is a risk of postinflamma-
tory hyperpigmentation, particularly in individuals with
darker skin types, therefore the dose must be adjusted to
prevent inflammation5. Adapalene, a naphthoic acid deri-
vative with retinoid activity, has shown similar effects on
melasma with less adverse effects compared to tretinoin20.
Azelaic acid
Azelaic acid is a naturally occurring, nonphenolic, sat-
urated, nine-carbon dicarboxylic acid that has no effect
on normally pigmented skin but only affects abnormal
melanocytes21. The supposed mechanism of action for
azelaic acid is competitive inhibition of tyrosinase22, inhi-
bition of reactive oxygen species and the reduction in
oxydative tissue injury and melanin formation23. It is
available in a cream at a concentration of 15 to 20% and
the recommended application is twice daily. Combination
of azelaic acid 20 % and tretinoin (either 0.05 or 0.1%)
has better therapeutic response than azelaic acid used
alone24. Adverse effects of the treatment include mild
and transient local pruritus, burning and stinging25.
Other adverse reactions such as erythema, dryness, rash,
peeling, irritation and contact dermatitis are extremely
rare.
Corticosteroids
Corticosteroids may directly affect the synthesis of
melanin, although the mechanism is not fully known.
Steroids may influence melanocyte function by inhibi-
tion of prostaglandin or cytokine production by epider-
mal cells26 and by suppressing secretion of metabolic
products from melanocytes27. Due to numerous adverse
events, such as steroid dermatitis, allergic contact der-
matitis28, atrophic changes, teleangiectasias, cortico-
steroids in monotherapy are not advisable therapeutic
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option. On the other hand, use of corticosteroids in com-
bination with hydroquinone and tretinoin has proven to
be successful treatment24.
Combination therapy
Epidermal type of melasma is most successfully trea-
ted by a combination of hydroquinone, steroid and tre-
tinoin. Kligman’s formula, that was proposed in 1975
(hydroquinone 5%, tretinoin 0.1%, and dexamethasone
0.1%) has been the most widely used. Despite its effec-
tiveness, this preparation has many side effects. Over the
years new formulas have been developed with less severe
side effects while maintaining or improving efficacy. The
best effect was observed by the avoidance of sunlight and
the use of the formulas containing low concentrations of
hydroquinone and retinoid acid1. New formulas with less
severe side effects are hydroquinone 2%, tretinoin 0.05%,
betamethasone valerate 0.1%, once daily for 10 weeks or
the combination of hydroquinone 4%, tretinoin 0.05%,
fluocinolone acetonide 0.01% do not cause skin atrophy
or thinning, rosacea or hypopigmentation29.
Other (potential) topical agents
Kojic acid
Kojic acid, a tyrosinase inhibitor, is not approved
treatment for melasma in some countries. It has been
studied in combination with hydroquinone or glycolic
acid in patients not responding to monotherapy with
other topical agents. Efficiency of kojic acid compared to
2% hydroquinone is approximate but with more adverse
reactions, such as irritation30.
L-ascorbic-2-phosphate
L-ascorbic-2-phosphate, is a stable vitamin C derivate
that supresses melanin production and may be effective
in reduction of hyperpigmentation31.
Flavonoids
Flavonoids from licorice roots (glabrene, isoliquiriti-
genin and liquirtin) have shown very good depigmen-
tation effect with only mild irritation as adverse effect32.
Physical therapies
Chemical peeling
Chemical peeling agents cause depigmentation by re-
moving melanin. Peels are better tolerated by individuals
with lighter skin, and caution is needed in darker ratial-
-ethnic groups because of postinflammatory hyperpig-
mentation and the aggravation of melasma itself. The
risk of complications increases with the depth of the
wound. Adverse reactions like erythema and infection
are lowest with superficial chemical peels. Several peel-
ing agents were studied like salicylic acid, trichloroacetic
acid, tretinoin and resorcinol, glycolic acid peels33 remain
the most popular. Application is simple, with rare ad-
verse reactions33. Glycolic acid peels at concentrations
from 10 to 70% are popular and can be used in dark-skin-
ned patients. They are usually applied once per month
for 3 consecutive months. Chemical peeling can stimu-
late melanogenesis thus causing aggravation of disease.
The use of 4% hydroquinone in a hydroalcoholic solution,
1% hydrocortisone acetate cream and 0.05% tretinoin
cream after chemical peeling is recommended to inhibit
the postinflammatory pigmentation, and should be used
until complete regeneration of skin15. After the treat-
ment the use of sunscreen is obligatory for indefinite pe-
riod of time.
Other (potential) physical therapies
Dermabrasion
Dermabrasion is not standard treatment modality be-
cause of adverse reactions like postinflammatory hyper-
pigmentation, milia, pruritus, keloid formation, although
in some studies melasma has been cleared without re-
currence2.
Intense pulsed light therapy
Intense pulsed light therapy (IPL) is an effective ther-
apeutic choice for epidermal melasma, but long-term sun
protection and bleaching creams should be used after
treatment in patients with mixed melasma34.
Laser therapy
Depending on wavelength of light emitted by laser de-
vice, light penetrates on different depth and therefore af-
fects different type of tissue. Melanin containing struc-
tures are affected by the wavelengths over 600 nm35.
Q-switche neodimium YAG laser36 was not effective in
the melasma treatment, as well as Q-switched ruby la-
ser37. In refractory melasma the combination of CO2 la-
sers and Q-switched alexandrite laser was unpredicta-
ble38. Erbium:YAG laser use was recommwended only for
refractory melasma39. The pigmented lesion dye laser
was ineffective in the treatment of deep dermal melasma.
No single laser treatment has been effective or superior
over topical agents. The use of erbium:YAG laser resur-
facing does improve melasma, but because of postin-
flammatory hyperpigmentationis recommended only for
refractory melasma.
Conclusion
Melasma should be treated using monotherapy or
combination of topical therapy, mainly fixed triple or
dual combinations containing hydroquinone, tretinoin,
corticosteroids or azelaic acid. Modified Kligman’s for-
mula manifests as very effective. Discontinuation of the
use of birth control pills, scented cosmetic products, and
phototoxic drugs coupled with UV protection are obliga-
tory measurements in combination with topical treate-
ment. Alternative treatments including chemical peels
(alone or in combination with topical therapy) seem to
have the best result as an alternative to bleaching creams.
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Laser treatments show limited efficacy and should rarely
be used in the treatment of melasma. Combining topical
agents like hydroquinone, tretinoin and a corticosteroid
in addition to sun avoidance, regular use of sunscreen
throughout the year and patient education is the best
treatment in this difficult to treat condition.
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NOVIJE SPOZNAJE U LIJE^ENJU MELASME
S A @ E T A K
Melasma je ~est ste~eni poreme}aj pigmentacije koji se javlja na fotoeksponiranim mjestima, naj~e{}e na obrazima,
~elu i iznad gornje usne. Melasma se mo`e javiti u oba spola, iako su 90% oboljelih `ene. ~e{}e se javlja u osoba tamnijeg
tipa ko`e (tip ko`e po Fitzpatricku IV, V i VI), pogotovo latinoamerikanci, azijati i afroamerikanci. Melasma se javlja u
pubertetu ili kasnije, dok se u osoba tamnijeg tipa ko`e javlja ve} u prvom desetlje}u `ivota. Uzrok melasme jo{ nije u
potpunosti poznat, ali su poznati mnogi predisponiraju}i faktori. Najva`niji su ekspozicija UV zra~enju i genetska pre-
dispozicija, i to u oba spola. Kod `ena, uz gore navedene ~imbenike, va`an je i hormonalni utjecaj. Od ostalih predis-
poniraju}ih faktora isti~u se stres i kozmeti~ki proizvodi koji sadr`avaju fototoksi~ne tvari. U terapiji melasme prva
linija lije~enja su lokalni pripravci, u monoterapiji ili kombiniranoj terapiji, uglavnom trojna terapija, koja se sastoji od
hidrokinona, tretinoina, kortikosteroida ili azelai~ne kiseline. U~inkovitom se pokazala i modificirana Klingmanova
formula. Uz nabrojene lokalne pripravke fotoprotektivna sredstva koja {tite od UVA i UVB zra~enja su naju~inkovitiji u
lije~enju epidermalnog tipa melasme. Dodatne, ali obavezne, mjere lije~enja su prekid uzimanja oralnih kontraceptiva i
fototoksi~nih lijekova te fotoza{tita. Kao druga linija lije~enja primijenjuju se kemijski piling i glikolna kiselina, a nakon
terapije lokalnim prirpavcima. Terapija laserom ima ograni~enu u~inkovitost i ne savjetuje se njegova upotreba za
lije~enje melasme. Kombinirani lokalni pripravci kao hidrokinon, tretinoin i kortikosteroidi, uz izbjegavanje izlaganja
suncu i upotreba fotoprotektivnih sredstava svakodnevno i tijekom cijele godine te edukacija bolesnika su najbolje
mjere za lije~enje melasme.
